Methylene blue (MB), the first synthetic drug, has a 120-year-long history of diverse applications, both in medical treatments and as a staining reagent. In recent years there was a surge of interest in MB as an antimalarial agent and as a potential treatment of neurodegenerative disorders such as Alzheimer's disease (AD), possibly through its inhibition of the aggregation of tau protein. Here we review the history and medical applications of MB, with emphasis on recent developments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neurobiolaging.2010.12.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lest we forget… Breast cancer & beyond….
Indian J Med Res
August 2024
Department of Psychiatry, All India Institute of Medical Sciences, New Delhi 110 029, India.
Vascular Repair in Wartime Casualties.
J Spec Oper Med
October 2024
F. Edward Hebert School of Medicine at the Uniformed Services University, Bethesda, MD.
In the third installment of the "Lest We Forget" series, the authors discuss a critical advance-vascular repair, pioneered by Dr. Carl Hughes-in the care of the war-wounded during the Korean War. This article reviews the management of large vessel injuries in wartime, the challenges and advances in military medicine during the Korean War, and the application of these lessons to current practices.
View Article and Find Full Text PDFLest we forget: Johann Alexander Vogelsang-a pioneer in maxillofacial surgery in East Germany.
J Med Biogr
August 2024
Department of Preventive Dentistry, Periodontology and Cariology, University Medical Center Göttingen, Göttingen, Germany.
Johann Alexander Vogelsang, a pioneering figure in maxillofacial surgery, played an important role in developing this field in East Germany, particularly in Dresden. Born in 1890, Vogelsang pursued dentistry against his family's wishes, studying at several German universities before his education was interrupted by the First World War. His experiences treating facial injuries during the war significantly influenced his professional focus.
View Article and Find Full Text PDFCritically Ill Older Adults' Representation in Intervention Trials: A Systematic Review.
Crit Care Explor
July 2024
Interdepartmental Division of Critical Care, Sinai Health System, University of Toronto, Toronto, ON, Canada.
Objectives: Older adults may be under-represented in critical care research, and results may not apply to this specific population. Our primary objective was to evaluate the prevalence of inclusion of older adults across critical care trials focused on common ICU conditions or interventions. Our secondary objective was to evaluate whether older age was used as a stratification variable for randomization or outcome analysis.
View Article and Find Full Text PDFDementia Screening: Lest We Forget.
JACC Heart Fail
May 2024
Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas, USA. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!